Islet Holdings Inc. offers a patented microencapsulation technology designed to protect transplanted islet cells from the recipient's immune system. This innovative approach enhances the survival and function of transplanted cells, leading to improved long-term outcomes for patients with insulin-dependent diabetes. The technology involves creating biocompatible microcapsules that shield the islet cells from immune attack, promoting successful integration and insulin production within the patient's body.